Supplementary Figure 5 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors

PDF file - 3331K, Representative examples of Everolimus-induced change in the activation of the AKT/mTOR and MAPK pathways assessed by immunocytochemistry. Decreased p-S6RP and p-p70S6K expressions by Everolimus (30 nM, a dose achievable in humans by oral administration) are detected in the FU-SFT8611 and HS-Sch-2 cell lines. p-AKT, p-mTOR, p-MEK, and p-ERK1/2 expressions show no obvious effect of Everolimus administration. Note that Everolimus treatment decreases the number of viable cells.